Intrinsiqq
Ipsen logo

Ipsen Financials

IPN.XPAR

⊜ Compare

All currency values in € millions unless otherwise noted

Scroll

Income Statement
DEC 2025
DEC 2024
DEC 2023
DEC 2022
DEC 2021
Revenues
Revenue€3,929€3,575€3,306€3,157€2,749
Cost of Revenue€751€704€571€528€439
Gross Profit€3,178€2,870€2,735€2,629€2,310
Total Operating Expenses€2,233€2,182€2,124€1,758€1,457
Operating Income€945€688€611€871€854
Non-Operating
Net Interest Expense-€44-€42-€38-€31-€24
Income Tax Expense€134€75€136€112€158
Net Income
Net Income€445€347€647€648€647
Per Share Data
Revenue Per Share€47.54€43.20€39.97€38.30€33.26
EPS (Basic)€5.37€4.18€7.79€7.87€7.82
EPS (Diluted)€5.32€4.15€7.73€7.81€7.76
Shares Outstanding82.7M82.8M82.7M82.4M82.6M
Dividends Per Share€1.60€1.40€1.20€1.20€1.20

Ipsen (IPN.XPAR) financials: revenue, profit and margins

Ipsen (IPN.XPAR) generated about €3.9 billion in revenue and €445 million in net income (a 11.3% net margin) over the trailing twelve months, growing at roughly 9.3% a year. Figures are from company filings; this is analysis, not investment advice.

Frequently asked

What is Ipsen's (IPN.XPAR) revenue?+

Ipsen generated about €3.9 billion in revenue over the trailing twelve months. Revenue has grown at roughly 9.3% a year over the past five years. Revenue is the top line, before any costs; what matters for value is how much of it survives to free cash flow. The full income statement, balance sheet and cash-flow statement are on this tab.

Is Ipsen profitable?+

Yes, Ipsen reported about €445 million in net income over the trailing twelve months, a net profit margin of roughly 11.3%. Net income is the bottom line after all costs, interest and taxes. Compare it to free cash flow on this tab, since reported profit and actual cash generated can diverge.

What are Ipsen's profit margins?+

Ipsen runs a gross margin of about 80.9%, an operating margin of about 24.1%, a net margin of about 11.3%. Margins show how much of each sales dollar a company keeps at each stage. Stable or rising margins usually signal pricing power and cost discipline; falling margins are worth investigating. See the multi-year trend on this tab.

How fast is Ipsen growing?+

Ipsen's revenue has compounded at roughly 9.3% a year over the past five years. Growth only creates value when it is profitable and cash-generative, so read this rate alongside IPN.XPAR's margins and free cash flow. This is analysis from company filings, not investment advice.

How the market compares: How many US companies are profitable

Peers

Drug Manufacturers - Specialty & Generic · Pick stocks to compare with IPN.XPAR

CompareIntrinsic value
BIM.XPARbioMérieux SA
€97.65+3.06%65
ORP.XPAROrpea
€10.20+2.93%26
GDS.XPARRamsay Générale de Santé SA
€8.62-1.37%49
CLARI.XPARClariane SE
€3.31+3.43%45
EMEIS.XPAREmeis SA
€10.20+2.93%56
LNA.XPARLNA Santé SA
€25.50+4.51%46
EAPI.XPAREuroapi S.A.S.U.
€0.82+2.11%46
GBT.XPARGuerbet SA
€6.26-0.95%38

Held by ETFs

IPN.XPAR is in 83 US ETFs. The largest of them, with IPN.XPAR's weight in each:

Spot a number that looks wrong?

Download this analysis as a PDF (Pro)

Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing IPN.XPAR

Create a free account and get 14 days of Premium: every stock and every tool.

  • Unlimited stocks
  • Stock screener
  • Portfolio tracker
  • Editable DCF
  • Compare side by side
  • Unlimited alerts

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

SectorsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.